

Bringing Life-Changing Therapies to Patients Everywhere

Veristat is proud to have supported the preparation of 84 marketing applications/marketing authorisations (NDA, BLA, MAA, etc.) that are now approved for patients. For these approved products, direct involvement included analysis and standardization of the clinical trial data, writing of the eCTD modules and/or electronic submission to the regulatory agencies.

84 PRODUCT APPROVALS — 57 FOR RARE DISEASES

2021 — 2022 16 APPROVALS -12 RARE DISEASE

2 Oncology: 1 NDA, 1 sNDA 7 Endo/Metabolic: 3 NDA, 2 BLA, 2 MAA

1 Cardiology: 1 BLA

3 Immunology: 2 NDA, 1 sNDA 2 Neurology: 1 NDA, 1 sNDA 1 Psychiatry: 1 NDA

> 2011 — 2015 18 APPROVALS -12 RARE DISEASE

9 Oncology: 1 MAA, 4 NDAs, 4 sNDAs 5 Endocrine/Metabolic: 2 BLAs,

2 MAAs, 1 NDA

2 Infectious Disease: 1 BLA, 1 NDA

1 Neurology: 1 NDA

1 Pain Management: 1 NDA

8 APPROVALS

In 2022, Veristat teams supported marketing applications for eight therapies that received regulatory approval.

2016 — 2020 37 APPROVALS -28 RARE DISEASE

17 Oncology: 3 BLAs, 3 MAAs, 6 NDAs,

1 iNDA, 3 sNDAs, 1 NDS

8 Endocrine/Metabolic: 3 MAAs, 2

NDAs, 3 jNDAs

4 Infectious Disease: 1 MAAs, 2 NDAs,

1 sNDA

3 Hepatology: 1 BLA, 1 NDA, 1 jNDA

2 Hematology: 1 MAA, 1 NDA

2 Neurology: 2 NDAs

1996 — 2010 13 APPROVALS - 5 RARE DISEASE

5 Oncology: 2 BLAs, 2 NDAs, 1 sNDA 4 Infectious Disease: 3 BLAs, 1 sNDA

2 HIV/AIDS: 1 BLA, 1 NDA

1 Cardiology: 1 NDA

1 Pain Management: 1 NDA

Contact Veristat Today

Let the Veristat science-minded experts guide your through the entire regulotory registration process. Contact Us.

www.veristat.com